Oncolytics Biotech Inc - Pelareorep联合疗法在二线KRAS突变MSS型结直肠癌中展现19.5个月中位缓解持续时间

美股速递
May 04

Oncolytics Biotech Inc宣布,其核心候选药物pelareorep联合疗法在针对二线治疗KRAS突变、微卫星稳定(MSS)型转移性结直肠癌(mCRC)的临床试验中取得积极数据。研究结果显示,该联合治疗方案的中位缓解持续时间达到19.5个月,展现出持久的抗肿瘤活性。

这一数据凸显了pelareorep在难治性结直肠癌患者群体中的治疗潜力,特别是针对KRAS突变这一常见且治疗挑战较大的亚型。较长的缓解持续时间可能为患者带来更显著的临床获益,也为后续临床开发提供了有力支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10